OriCAR-017 not checked
OriCell Therapeutics Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Relapsed and/or Refractory Multiple Myeloma, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorders, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias and 7 more
- Main trialPhase 1/2
- “An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM”In the company’s words, NCT06182696 on ClinicalTrials.gov
Other drugs for Relapsed and/or Refractory Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up2
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 12 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Nov 2026 | OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM | |
| Phase 1Recruiting | 12 Dec 2026 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026